Alterity CEO disposes 47,620 options at $0.50

ATHE’s CEO and director reported the disposal of a 47,620-contract listed option position linked to Alterity’s ordinary shares.

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.

Insider Trade Summary

Net Buyer: 47,620 shares

Net Buy 1 txn

Insider Stamler David Allen

Role Chief Executive Officer

Bought 47,620 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Listed option exp 31 Aug 2026	47,620	$0.50	$24K

Holdings After Transaction: Listed option exp 31 Aug 2026 — 0 contracts (Direct)

Key Figures

Listed options transacted: 47,620 options Reported price per listed option: $0.50 per option Underlying ordinary shares: 47,620 shares +4 more

7 metrics

Listed options transacted 47,620 options Derivative transaction reported for August 31, 2026

Reported price per listed option $0.50 per option Derivative transaction on August 31, 2026

Underlying ordinary shares 47,620 shares Shares underlying the listed options expiring August 31, 2026

Post-transaction listed option holdings 0 options Total derivative securities of this listed option series held directly after transaction

Conversion or exercise price $0.50 per share Exercise price of the listed options expiring August 31, 2026

Option expiration date August 31, 2026 Expiration date of the listed options involved in the transaction

Option exercise date April 15, 2026 Exercise date field for the listed options tied to ordinary shares

Key Terms

Listed option, underlying security, derivative securities, Rule 10b5-1

4 terms

Listed option financial

"Security title is given as “Listed option exp 31 Aug 2026”"

underlying security financial

"The filing names the underlying security title as “Ordinary shares”"

derivative securities financial

"The transaction is classified as involving derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Rule 10b5-1 regulatory

"A document-level Rule 10b5-1 checkbox indicates plan status"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ATHE’s CEO report on this Form 4?

David Allen Stamler, ATHE’s Chief Executive Officer and director, reported a disposition involving 47,620 listed options tied to Alterity Therapeutics’ ordinary shares, with the transaction date reported as August 31, 2026.

What was the size and price of the derivative position reported for ATHE?

The filing shows a transaction in 47,620 listed options with a reported price of $0.50 per option. Each option relates to one underlying ordinary share, for 47,620 underlying shares in total.

What type of security was involved in the ATHE Form 4 transaction?

The transaction involved a derivative security described as a “Listed option exp 31 Aug 2026”, with an underlying security title of “Ordinary shares” of Alterity Therapeutics Ltd.

What are David Allen Stamler’s reported holdings after this ATHE option transaction?

For this specific listed option series, the Form 4 reports 0 derivative securities held directly following the transaction. The filing does not list additional derivative positions in its derivative summary.

Was the ATHE insider transaction made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked as affirmative, indicating the filing does not affirm that the reported transaction was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 06:52 PM EDT Accepted by SEC EDGAR 09/08/2026 - 06:52 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stamler David Allen

(Last) (First) (Middle)

39899 BALENTINE DRIVE

(Street)

NEWARK CALIFORNIA 94560

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol
[ATH.ASX]

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Listed option exp 31 Aug 2026	$0.5	08/31/2026		P			47,620	04/15/2026	08/31/2026	Ordinary shares	47,620	$0.5	0	D

Explanation of Responses:

	David Allen Stamler	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)